About | Contact | Blog | Home

8TH ANNUAL LIFE SCIENCE CHIEF EXECUTIVE OFFICER FORUM

MARCH 23–24, 2017 | SAN DIEGO, CA Download AgendaRegister Now

DAY ONE | THURSDAY, MARCH 23RD

7:00 REGISTRATION & MORNING COFFEE

7:50 CHAIRPERSON’S OPENING REMARKS
Matthew L. Cohn, Senior Vice President & Senior Program Manager, Life Science & Medical Products Solutions
ALLIANT INSURANCE SERVICES

Live Poll: What factors do you believe are impacting the success of life science companies today?

8:00 STATE OF THE INDUSTRY PANEL: CURRENT FACTORS INFLUENCING LIFE SCIENCE COMPANIES
CEOs from pharmaceutical and medical device companies face an ever-evolving healthcare landscape, and as such encounter different challenges and obstacles on a regular basis, with little or no predictability related to what might come next. From value-based healthcare to the impact of the new administration, this panel discussion will address various factors impacting the life science industry today while forecasting future implications on manufacturers and external stakeholders. Additionally, the use of live polling throughout this session will uncover audience perspectives on the current life science environment.

  • Initiatives and influence of the new administration
  • Raising capital: the environment for funded innovation
  • Opportunities for collaboration with regulatory agencies
  • Assessing the continued impact of value-based healthcare
  • Pricing & reimbursement: the current landscape

Interviewer: Thad Bench, Chief Executive Officer, BENCHWORKS

Paul C. Grint, MD, President & Chief Executive Officer
REGULUS THERAPEUTICS

Michael B. Nichol, PhD, Professor of Public Policy
UNIVERSITY OF SOUTHERN CALIFORNIA

Byron S. Kalogerou, Partner, Chair, Life Science Industry Group
MCDERMOTT, WILL & EMERY

Brendan Benner, Vice President, Public Affairs, MDMA

Mark DuVal, JD, President, DUVAL & ASSOCIATES

 

8:40 FINANCING THE GROWTH OF LIFE SCIENCE COMPANIES WITHOUT SUFFERING EQUITY DILUTION
For those believing in the future increase of enterprise value, a primary concern must be shareholder equity retention. Equity retention is or should be a major concern in the negotiation of capital raising, executive recruitment and retainment, specific project and product development, mergers, acquisitions and capitalization restructuring. Debt and equity exchanges for royalties can adjust capitalization and provide for greater management flexibility. Royalties, an agreed percentage of defined revenues, for an agreed period, can be redeemable with a range of possible terms and conditions. Arthur Lipper developed and patented an approach to using royalties in the financing of businesses and is the authority regarding the creation and use of royalties.

Arthur Lipper, Chairman, BRITISH FAR EAST HOLDINGS LTD.

 

9:10 NETWORKING MEETINGS & COFFEE BREAK

 

Live Poll: Over the next 2-3 years, how positively will capital markets view life science funding?

 

10:10 PANEL DISCUSSION: RAISING CAPITAL IN TODAY’S FINANCIAL MARKET
Central to the success of a start-up and emerging growth company is a CEO’s ability to secure adequate capital from a variety of sources including institutional and private investors while minimizing dilutive funding. Financing for life science companies can be a rollercoaster of ups and downs, dependent on the financial market and investor outlook, often encouraging CEOs to seek alternative funding vehicles, in addition to venture capital firms. Angel investors, matching foundation grants, bank loans and other non-dilutive funding sources can assist in boosting cash flow to support operating and product development costs. Through the lens of various perspectives within the industry, this panel discussion will address the current state of capital markets and how life science companies can ensure continued fundraising success by overcoming intrinsic financing challenges.

  • Risk-averse investors & the impact on emerging life science companies
  • Responding to investor reluctance to support innovative technologies
  • Opportunities for government and public sources of funding
  • Examples of recent funding experiences in the life science industry

Moderator: Guy Smith, BRANDING SCIENCE

Panelists:
Vijay B. Samant, VICAL INCORPORATED

Arthur Lipper, BRITISH FAR EAST HOLDINGS LTD.

Robert L. Gershon, BOVIE MEDICAL

 

10:50 HOW EINSTEIN’S DEFINITION OF INSANITY COULD WREAK HAVOC IN YOUR LIFE SCIENCE BUSINESS
Property and Casualty Insurance for the average company in the Life Science Industry is extremely complex and far outside the scope of the average local insurance broker that insures restaurants, contractors and general business. To say the “devil is in the detail” would be quite an understatement. During this presentation you will learn through various client case studies the systematic steps and decision logic needed to avoid the “havoc” and most optimally protect shareholder value.

Matthew L. Cohn, Senior Vice President & Senior Program Manager, Life Science & Medical Products Solutions
ALLIANT INSURANCE SERVICES

 

11:30 CASE STUDY: TRANSFORMING A COMPANY’S NARRATIVE FOR GROWTH TO SUPERCHARGE INVESTOR BUY-IN
20 percent annual growth. This is the simple narrative that Bovie Medical communicated to its investor community at the start of 2016. Rather than sharing a complex web of operational metrics, the senior leadership team streamlined its goals for growth to a straight-forward percentage, allowing investors to precisely hold the company accountable as it honors its commitment to 20% annual growth. Acknowledging its pledge to stable, continued growth transcends the entire organization and pervades throughout the company’s vision and ongoing strategic plan.

Robert L. Gershon, Chief Executive Officer, BOVIE MEDICAL

 

12:00 LUNCHEON FOR ALL ATTENDEES, SPEAKERS & SPONSORS
TABLE TOPICS:
During lunch, attendees are encouraged to continue networking and use this time for focused discussion. Table Topics will be concentrated on the healthcare environment.

  • Do you think value-based healthcare is here to stay?
  • How do you think the healthcare system will evolve over the next 4 years?
  • What are the biggest healthcare factors impacting the life science industry?

 

Live Poll: What does company growth mean to you?

 

1:00 PANEL DISCUSSION: WHAT DOES GROWTH MEAN TO YOU?
For one life science company, 20% annual growth is considered the key to continued success; however, philosophies on significant growth can vary from company to company and from CEO to CEO. Whether it is a sharpened focus on developing an innovative product internally or a multi-pronged approach that includes the acquisition of external products, identifying and reshaping an optimal growth strategy is critical to the sustainability of a pharmaceutical or medical device corporation. This dynamic panel discussion will offer attendees a variety of perspectives on how senior management teams developed and committed to a growth plan, while also recognizing the need to implement a nimble strategy that can be altered based on current market trends.

  • Deciphering differing views on company growth
  • Demonstrating and maintaining continued growth
  • Communication of company vision and goals
  • Meeting investor expectations for success
  • External factors that may alter an existing plan

Robert L. Gershon, BOVIE MEDICAL

David J. Mazzo, PhD, CALADRIUS BIOSCIENCES

Mark C. Throdahl, ORTHOPEDIATRICS

Khush F. Mehta, CARDIODX

Rajesh C. Shrotriya, MD, SPECTRUM PHARMACEUTICALS

 

1:40 PANEL DISCUSSION: INCORPORATING THE PATIENT PERSPECTIVE INTO PRODUCT LAUNCH & COMMERCIALIZATION
Even after the clinical trial phase, the patient perspective must permeate all aspects of product launch and commercialization as they are ultimately the end stakeholder of these innovative therapies and medical devices. As life science companies prepare for commercialization, incorporating the patient into market research and marketing plans is paramount to the success of a product launch. Additionally, pharmaceutical and medical device manufacturers can combine product data with the ability to connect emotionally and technically with customers to ensure market adoption.

Michael Narachi, President & CEO, OREXIGEN THERAPEUTICS

Raymond Huggenberger, Chief Executive Officer & Director, INOGEN

Clinton H. Severson, Chairman & Chief Executive Officer, ABAXIS

 

2:20 NETWORKING MEETINGS & COFFEE BREAK

 

3:00 CULTURE AS A COMPETITIVE WEAPON
A small company’s culture is a powerful source of competitive advantage. It is much easier to get culture right in a start-up than in a larger, established company. The right culture can make your organization more agile, more productive, and is a powerful weapon in competing against larger companies. This presentation will suggest some simple things you can do to establish a great culture:

  • Hire for personal attributes in addition to experience
  • Create a hierarchy of good ideas, not a hierarchy of people, by delegating decision making
  • Balance people-focus with performance-orientation
  • Model leadership behaviors using the mnemonic device, L-E-D-R-S-H-I-P
  • Keep performance appraisals and 360 degree feedback simple so they are effective
  • Develop a corporate cause that captures the hearts and minds of your people

Mark C. Throdahl, President & CEO, ORTHOPEDIATRICS

 

Live Poll: How well does your organization incorporate the patient perspective?

 

3:40 KEYNOTE FIRESIDE CHAT: LEADERSHIP EXCELLENCE IN THE LIFE SCIENCE INDUSTRY
Leading a corporation from inception to a fully-established commercial entity requires time, dedication and expertise, and those companies thriving in this field are led by individuals of the highest caliber, who understand what it takes to identify market needs, match products to those needs, and meet scientific, regulatory and commercial milestones in order to succeed. In this fireside chat, Founder, President & CEO of ARMO Biosciences Peter Van Vlasselaer will walk attendees through his 20+ years of experience in the biotech industry and as a CEO at Avidia and Arresto Biosciences

Peter Van Vlasselaer, PhD, Founder, President & CEO, ARMO BIOSCIENCES

 

4:20 QUICK STRETCH BREAK

 

4:30 WORKSHOP: CHAMPIONING DIVERSITY & INCLUSION IN THE LIFE SCIENCE WORKPLACE
With innovation at the forefront, life science manufacturers must consider the impact a diverse workforce can have on identifying and executing ideas that will boost an organization’s continued success and profitability. To compete in an ever-changing marketplace that demands novel therapies and medical devices, a wide range of perspectives and experiences is needed, and life science leadership teams are responsible for supporting diversity and inclusion to achieve desired business results. This interactive workshop will empower CEOs with the tools and commitment to ensure an atmosphere of inclusion across a life science company.

  • Understanding and communicating the business case for diversity & inclusion
  • Counteracting hidden biases that impede diverse talent acquisition and inclusive leadership
  • Leading in ways that create greater employee engagement, productivity and retention in a diverse workforce

Amber L. Mayes, President & Founder, AMBER MAYES CONSULTING

 

5:30 NETWORKING MEETINGS & COCKTAIL HOUR

6:30 END OF DAY ONE FORUM ACTIVITIES

 

Q1 Productions
500 N. Dearborn, Suite 500 | Chicago IL 60654 | U.S.
Phone 312 822 8100 | Fax 1 312 602 3834


Copyright 2013 Q1 Productions - All Rights Reserved Privacy Policy

Share This